Hill February 17, 2024
Tara Suter

The Food and Drug Administration (FDA) announced Friday that it approved a ground breaking cellular therapy treatment for patients with advanced melanoma, and surgery has been unsuccessful.

Amtagvi, a type of T-cell therapy, involves boosting immune cells within tumor tissue to help the body fight off the cancer. During the treatment, the patient’s t-cells are separated from the tumor, artificially multiplied and then returned to them via infusion, the FDA said in a press release.

“Unresectable or metastatic melanoma is an aggressive form of cancer that can be fatal,” said Peter Marks, the director of the FDA’s Center for Biologics Evaluation and Research (CBER), said in a press release. “The approval of Amtagvi represents the culmination of scientific and clinical...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
5 Digital Health Areas To Be Impacted By The FDA Layoffs
FDA Approves First Biosimilar to Omalizumab
Trump's Nominees to Run FDA, NIH Get Greenlighted by Senate Committee
FDA Debuts a New Communications and Compliance Tool for Device Data Integrity Concerns
HHS Explores Stronger FDA Oversight for Food Ingredients

Share This Article